• In the past quarter, Neuronetics reported preliminary fourth-quarter 2025 revenue of US$41.8 million, driven by demand for its NeuroStar systems and clinic operations, and generated US$0.9 million in positive operating cash flow.
• This combination of strong top-line growth and the shift to positive operating cash flow highlights progress in scaling its NeuroStar-focused business while managing liquidity pressures.
• Next, we’ll explore how the move to positive operating cash flow may influence Neuronetics’ existing investment narrative and risk profile.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.

Neuronetics Investment Narrative Recap

To own Neuronetics, you need to believe in wider adoption of NeuroStar-based treatments and the clinic platform, while accepting execution and balance sheet risk. The shift to positive operating cash flow is encouraging, but it does not fully offset concerns around high leverage and historically thin margins in the clinic and SPRAVATO segments, which remain key near term risks and catalysts for sentiment.

Among recent developments, the exclusive three year agreement with Elite DNA Behavioral Health stands out alongside the preliminary Q4 beat. Together, these point to growing utilization of NeuroStar systems and clinics, which supports the revenue side of the story even as investors continue to watch whether cash generation can keep pace with debt obligations and elevated operating costs.

Yet behind the improving cash flow, there is still the issue of a high debt load that investors should be aware of...

Neuronetics' narrative projects $199.1 million revenue and $24.9 million earnings by 2028. This requires 21.5% yearly revenue growth and a $73.7 million earnings increase from -$48.8 million today.

Uncover how Neuronetics' forecasts yield a $6.50 fair value, a 358% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value Neuronetics between US$2.28 and US$6.50, highlighting very different expectations. When you set those views against the company’s reliance on lower margin clinic revenues, it becomes clear why performance outcomes could vary and why it helps to weigh several perspectives before forming your own view.

Explore 3 other fair value estimates on Neuronetics - why the stock might be worth over 4x more than the current price!

Build Your Own Neuronetics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Neuronetics research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Neuronetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neuronetics' overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Outshine the giants: these 28 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.